Safety and efficacy of allogeneic hematopoietic stem cell transplantation for refractory hematological malignancies with plerixafor-combined myeloablative conditioning
Not Applicable
Completed
- Conditions
- acute leukemia, myelodysplastic syndrome, chronic myelogenous leukemia
- Registration Number
- JPRN-UMIN000009485
- Lead Sponsor
- Division of Hematology Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
Moderate or severe dysfunction in major organs
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse events within 28 days after transplantation
- Secondary Outcome Measures
Name Time Method 1) neutrophil engraftment 2) red cell and platelet engraftment 3) non-relapse mortality with 28 days after transplantation 4) 1-year overall and non-relapse survivial 5) 1-year relapse rate 6) acute and chronic GVHD 7) Infectous complications